ReviewRheumatology international2008
The potential utility of B cell-directed biologic therapy in autoimmune diseases.
Review in Rheumatology international, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 44 citations in OpenAlex.
- Update on non-infectious uveitis treatment: anti-TNF-alpha and beyond.Frontiers in ophthalmology · 2024Review
- Article
- The Role of TLR4 on B Cell Activation and Anti-Journal of immunology research · 2016Review
- Use of rituximab in histologically confirmed idiopathic inflammatory myositis: a case series.Clinical rheumatology · 2015Article
- Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis.Rheumatology international · 2011Article
- Churg-Strauss syndrome successfully treated with rituximab.Rheumatology international · 2011Article
- Practical considerations on the use of rituximab in autoimmune neurological disorders.Therapeutic advances in neurological disorders · 2010Article
- Receptor crosstalk: reprogramming B cell receptor signalling to an alternate pathway results in expression and secretion of the autoimmunity-associated cytokine, osteopontin.Journal of internal medicine · 2009Review
- Monoclonal antibody treatments for multiple sclerosis.Current treatment options in neurology · 2009Article
- Overall reduction in antibody production could contribute to generate pathogenic autoantibodies and autoimmune manifestations.Clinical rheumatology · 2009Article
- Monoclonal antibody treatments for multiple sclerosis.Current neurology and neuroscience reports · 2008Review
- Rituximab treatment of collapsing C1q glomerulopathy: clinical and histopathological evolution.Pediatric nephrology (Berlin, Germany) · 2008Article
- Severe multi-resistant pemphigus vulgaris: prolonged remission with a single cycle of rituximab.Anais brasileiros de dermatologiaArticle
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Increasing awareness of the importance of aberrant B cell regulation in autoimmunity has driven the clinical development of novel B cell-directed biologic therapies with the potential to treat a range of autoimmune disorders. The first of these drugs-rituximab, a chimeric monoclonal antibody against the B cell-specific surface marker CD20-was recently approved for treating rheumatoid arthritis in patients with an inadequate response to other biologic therapies. The aim of this review is to discuss the potential use of rituximab in the management of other autoimmune disorders. Results from early phase clinical trials indicate that rituximab may provide clinical benefit in systemic lupus erythematosus, Sjögren's syndrome, vasculitis, and thrombocytopenic purpura. Numerous case reports and several small pilot studies have also been published reporting the use of rituximab in conditions such as myositis, antiphospholipid syndrome, Still's disease, and multiple sclerosis. In general, the results from these preliminary studies encourage further testing of rituximab therapy in formalized clinical trials. Based on results published to date, it is concluded that rituximab, together with other B cell-directed therapies currently under clinical development, is likely to provide an important new treatment option for a number of these difficult-to-treat autoimmune disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.